Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feedergsk.com
Press releases
Get the latest updates from Press releases directly as they happen.
Follow now 582 followers
Latest posts
Last updated 8 days ago
GSK’s RSV vaccine, Arexvy, receives European approval for expanded use in all adults 18 years and older
8 days ago
In the EU, an average of 158,000 adults are hospitalised with RSV-related...
Trelegy Ellipta approved in China for use in adults with uncontrolled asthma
11 days ago
Asthma indication introduces an important option for patients with uncontrolled symptoms
GSK enters agreement to acquire RAPT Therapeutics
14 days ago
Acquisition adds to Respiratory, Immunology & Inflammation pipeline
GSK, Pfizer and Shionogi agree on changes to ViiV Healthcare shareholding
14 days ago
Following Pfizer’s exit, Shionogi’s holding increases to 21.7%, with GSK maintaining 78.3%...
GSK’s Shingrix (Recombinant Zoster Vaccine) prefilled syringe presentation approved by the European Commission
27 days ago
Prefilled syringe offers healthcare professionals a convenient administration option.
GSK announces positive results from B-Well 1 and B-Well 2 phase III trials for bepirovirsen, a potential first-in-class treatment for chronic hepatitis B
27 days ago
Bepirovirsen demonstrated a statistically significant and clinically meaningful functional cure rate
Exdensur (depemokimab) approved in Japan for severe asthma and chronic rhinosinusitis with nasal polyps
28 days ago
Exdensur is the first and only ultra-long-acting biologic in Japan for the...
Nucala (mepolizumab) approved in China for use in adults with chronic obstructive pulmonary disease (COPD)
29 days ago
Nucala is the first and only monthly biologic approved in China studied...
GSK enters agreement with U.S. government to lower drug prices and expand access to respiratory medicines for millions of Americans
about 2 months ago
Voluntary agreement delivers on all four of President Trump’s requests and reduces...
Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma
about 2 months ago
SWIFT data included reduction in exacerbations requiring hospitalisation and/or emergency department visits...
Exdensur (depemokimab) approved in the UK for treatment of asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps
about 2 months ago
Approval based on data from the SWIFT and ANCHOR phase III trials.
Nucala (mepolizumab) receives positive CHMP opinion for treatment of chronic obstructive pulmonary disease (COPD)
about 2 months ago
Nucala is the only monthly biologic studied in a wide COPD population...